The biggest selling drug , Keytruda, has 31 different FDA approvals. That’s why it so valuable!
If one takes the time to read the company presentation, it’s clear IMU is using the same strategy to create value.
The presentation highlights EXPANSION trials for AZER-Cel , Vaxinia, Oncarlytics.
When BP comes to run the ruler over IMU they will find mountains of data. In many different cancers. Following the path beaten by Merck.
That’s 3 platforms which are all interconnected. Azer-cel being our very own CD19 CarT therapy can be used standalone or in combo with Oncarlytics.
Marck is valued at $360bn with 50% of sales from one drug Keytruda , which only has 4 years left of patent protection.
What LC and IMU are creating here is absolutely unique. Both the Azer-Cel and VAXINIA platform are already proven . And ticked off by the FDA, for progression towards approvals .
So far ONCARLYTICS has proven to be safe and well tolerated. All we need now is proof of efficacy as a mono or combo therapy.
It really is hard to understand why so many people are dissatisfied with the progress.
Sounds like they need somebody to hold their hand so they don’t wet the bed!
IMU Price at posting:
5.7¢ Sentiment: Buy Disclosure: Held
